481results about How to "Ensure medication safety" patented technology

The invention relates to a system and a method for drug placement, distribution and source tracing based on digital tags. The system is formed by connecting the following devices in a wired local network and a wireless local network inside a hospital: a drug placement, distribution and source tracing application server connected with a service database, a plurality of drug placing terminals, a single drug distributing terminal, a source tracing management terminal and an HIS (Hospital Information System) interface terminal interacting information with an HIS system. The system is a set of information system for drug placement, distribution and source tracing constructed by adopting a computer technology, an RFID (Radio Frequency Identification Devices) technology and a two-dimensional code technology. The information system is used for supporting hospital staff to complete two operating steps of drug placement in pharmacies and drug distribution in sick rooms during the drug circulation inside the hospital based on the digital tags, providing scientific and visualized examination means and tools and monitoring and checking each key link during drug placement and distribution. The system can realize the safe control mechanism of drugs for treating patients during the circulation inside the hospital and can reduce the accident potential caused by human mistakes.

The invention provides a safe medication monitoring system and a monitoring method thereof. The system comprises: a database, a medication rule base, and a monitoring device. The database is used to store data information related to past medical history of a to-be-examined patient. The data information comprises: basic information of the to-be-examined patient, and disease information, examination results, medication information, allergic history, and treatment information of the patient in past medical history. The medication rule base is used to store safe medication rules. The monitoring device determines whether medicine in a medication prescription is safe for the to-be-examined patient according to the database and the data stored in the medication rule base, and generates early warning information when the medicine is determined to be not safe. The system and the method monitor medicine in a given medication prescription in time, so as to ensure safe medication.

The present invention provides a butyl phthalide raw material drug product with the butyl phthalide content not less than 99.0%; the raw material drug is stable in quality, and can ensure the clinical curative effect and drug safety of a butyl phthalide preparation.

The invention discloses a recombinant melittin and an application thereof, and belongs to the technical field of genetic engineering. An amino acid sequence of the recombinant melittin protein is shown in the formula SEQ ID NO.1. The recombinant melittin protein sequence can be utilized for a preparation of gene medicines utilized for preventing and treating fallopian tubal diseases of breeding hens, in other words, the recombinant melittin protein sequence is connected with a carrier pVAX1 to form a recombinant melittin expression carrier. In addition, a CMV promoter of the carrier pVAX1 is replaced by a chicken ovalbumin gene end 5' regulatory sequence which is an ov sequence, thus the recombinant melittin can be expressed specifically in chicken fallopian tubal tissue. The recombinant melittin and the gene medicines have the advantages of good effects of treating fallopian tubal diseases of breeding hens, safety, no toxicity and broad application prospect.

The invention relates to a method for predicating novel curative effects of a medicament based on a biological process, which is disease-oriented and used to predicate a potential novel treating function of the medicament based on a medicament-disease relevance of a biological process spectrum. The method comprises the following steps of: (1) constructing a disease biological process spectrum and a medicament biological process spectrum; (2) calculating medicament-disease relevance scores on the layer of the biological process spectrum; (3) judging the significance of the relevance scores; and (4) screening a medicament-disease relation with the significance and carrying out further experimental demonstration on functions of the medicament by a user according to a sequencing result of the relevance scores. The invention further relates to an application of the method to the predication of the novel curative effects of the medicament. The predication method provided by the invention is ingenious in design, can be used for more comprehensively evaluating the medicament-disease relation, has important meanings of looking for novel medicaments for treating diseases, finding potential toxic or side effects of the medicaments, expanding a treating function space of the traditional medicaments, developing new uses for approved medicaments and the like, and is suitable for being popularized and applied on a large scale.

The invention discloses a medicinal azacitidine freeze-drying powder injection for treating myelodysplastic syndrome and a preparation method thereof. The prescription of the azacitidine freeze-drying powder injection comprises azacitidine, mannitol and vitamin C. The invention solves the problem of rapid impurity increase caused by different crystal forms formed in the processes of rapidly freezing and drying the prior powder injection by optimizing the prescription and improving the preparation method.

The invention aims to provide a method for preparing deproteinized calf blood extract and freeze-dried powder thereof. The method has simple process and is easy for mass production, the obtained extract has high bioactivity and good product purity, the freeze-dried powder is subjected to gradient temperature rise and drying, and the finished product has good appearance and is easy to dissolve. The deproteinized calf blood extract is prepared by the method comprising the following steps: heating collected blood serum and deproteinizing the blood serum, filtering the blood serum and then condensing the filtrate, removing protein by ethanol; then adding active carbon and acid into the filtrate to hydrolyze and decolor the filtrate; filtering the filtrate and then adjusting pH value to a proper range, freezing the filtrate and removing protein repeatedly; and finally using fibrous membrane to hyperfiltrate high molecular substance to obtain the deproteinized calf blood extract, then adding excipient and water for injection into the extract, pre-freezing the extract, and heating the extract in gradient and drying the extract in vacuum to obtain finished products.

An inclusion compound of cefuroxime axetil with high solubility, stability and activity contains cefuroxime axetil and the pharmacologically acceptable cyclodextrin chosen from alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and their derivatives. Its preparing process is also disclosed.

The present invention relates to a transportation system for the genetic medicine and the preparation method. The transportation system is a composite consisting of the genetic medicine, the cationic peptide or the polymer and any selected adjuvant ingredient. The composite is packaged in a nano particle of polymer material modified by the PEG. The ligand modification is conducted in the nano particle surface. The preparation method comprises the following steps. Step one, the genetic medicine, the cationic peptide or the polymer and any selected adjuvant ingredient are mixed in order to prepare the composite solution; step two, the organic solution of the polymer material is added into the composite solution and dispersed into the water phase, therefore the W/O/W-typed multiple emulsion is prepared, followed by separation of the collected nano particles; step three, the nano particle surface modified by the ligand and the collected nano particles are separated after modification. The stability of the genetic medicine in the preparation process and the encapsulation efficiency are both improved in the system. The surface modification not only prolongs the plasma half-life and improves the targeting property in the transportation system, but also enhances the transfection efficiency and greatly reduces the cytotoxicity in the transportation system, which therefore guarantees the safety of the medicine application.

The invention discloses a headspace gas chromatography method for determining the residual quantity of an organic solvent in a glycine bulk drug. The method is implemented under conditions that a DB-624 capillary column and a hydrogen flame ionization detector are used, sample inlet temperature is 150 DEG C, the detector temperature is 250 DEG C, high purity nitrogen is taken as carrier gas with flow rate being 2.2 mL/min, the split ratio is 10:1, headspace heating temperature is 80 DEG C, and equilibrium time is 35 min; besides, glycine is easily soluble in water and the 12 solvents are soluble in water to a certain degree, so that an aqueous solvent is adopted. The method can be used for simultaneously determining the residual quantity of the 12 organic solvents including methanol, ethanol, acetone, isopropanol, acetonitrile, dichloromethane, n-propanol, ethyl acetate, tetrahydrofuran, cyclohexane, n-butanol and toluene in the glycine bulk drug, has the characteristics of being easyto operate, quick, sensitive and accurate in result, and provides reference for effectively controlling the quality of the glycine raw material and ensuring medication safety.

The invention discloses a flucloxacillin sodium compound and a method for preparing the same. The method comprises that: firstly, N'N-dibenzylethylene diamine salt and flucloxacillin acid are mixed and reacted to form a salt; and secondly, high-purity flucloxacillin sodium is obtained through the displacement of a cation exchange resin. The invention adopts a purification method which is simple and easy to operate, thereby greatly improving the purity of the flucloxacillin sodium compound to a certain degree, removing a large amount of high molecular polymers, stabilizing the product quality of related preparations and ensuring the safety of clinic medication use.

The invention discloses an electronic prescription circulation method which comprises a step of receiving an electronic prescription sent by a hospital terminal, wherein the electronic prescription comprises medication information and basic information of a user, a step of carrying out reasonable medication examination on the medication information of the electronic prescription, a step of generating a corresponding drug taking pharmacy recommendation list according to the medication information when the medication information examination is approved, a step of sending the drug taking pharmacyrecommendation list to a corresponding user terminal according to the basic information of the user, a step of receiving drug taking pharmacy selection sent by the user terminal, and a step of pushing the electronic prescription to a corresponding pharmacy terminal according to the drug taking pharmacy selection. The invention also provides an electronic prescription circulation server and system, the electronization of a medical prescription is realized, the user can conveniently view the prescription in real time and carry and store the prescription, intelligent pharmacy recommendation is achieved, and the user can conveniently take medicines.

The embodiment of the invention provides a medicine recommendation method and device. The method comprises the steps of receiving personal information input by a user, wherein the personal information comprises at least one of symptoms, ages, genders, disease sites, medical history and medicine allergy history; searching a medicine knowledge base according to the personal information, and obtaining a first medicine list according to a search result, wherein the medicine knowledge base is constructed according to medicine books and/or network inquiry data; screening the medicines in the first medicine list according to a preset medicine inference library to obtain a second medicine list, so as to push the second medicine list to the user, wherein the medicine inference library is constructed through an inference engine according to medicine recommendation rules and the medicine knowledge base. According to the embodiment of the invention, proper medicines can be accurately recommended to the user on the premise of ensuring the medicine use safety of the user, so that the medicine use experience of the user is improved.

The invention provides a butylphthalide medicine active composition, which comprises the following ingredients: first ingredients: the butylphthalide content is higher than or equal to 98.0 percent; second ingredients: the second ingredients are one kind of materials or several kinds of materials selected from methylene phthalide, ethylene phthalide, propylene phthalide, butane phthalide, amylene phthalide, phthalide, methyl phthalide, ethyl phthalide, propyl phthalide and amyl phthalide, in addition, the content of the second ingredients is higher than 0 but is lower than or equal to 2.0 percent, when the second ingredients comprise any one kind of materials from methylene phthalide, ethylene phthalide, propylene phthalide, butane phthalide and amylene phthalide, the content of any one kind of included ingredients does not exceed 0.5 percent, and when the second ingredients comprise any one kind of materials from phthalide, methyl phthalide, ethyl phthalide, propyl phthalide and amyl phthalide, the content of any one kind of included ingredients does not exceed 1.0 percent. The quality of the medicine active composition is stable, and the clinic curative effect and the medication safety of the butylphthalide preparation can be ensured.

The invention discloses a preparation method of a Flos Trollii Flavonoid for injection. The extract of the Flos Trollii Flavonoid substantially comprises orientoside, vitexin, etc., flavone ingredients, the flavonoid content of which is more than 70 percent. The invention discloses the preparation method of the extract, which is mainly characterized in that the extract is acquired through refined treatment with twice column chromatography; the adsorption materials adopted are two among macroporous resin, polyamide or silica gel, reverse phase silica gel and gelatin and so on; the extract is prepared with modern technology of extraction, concentration and refining; the method is simple and easy to operate, improves the effective component purity of the raw medicinal materials and reduces the dosage and adverse reactions.

The invention discloses a preparation method and a detection method of a roflumilast material. The preparation method comprises the following steps: mixing 3-cyclopropyl methoxy group-4-difluoro methoxy group benzoic acid SM-1, thionyl chloride, dimethyl formamide with toluene, and carrying out an acylating chlorination reaction to obtain a midbody 1; mixing 3,5-dichloro-4-aminopyridine SM-2, tetrahydrofuran with potassium tert-butoxide and carrying out a salt forming reaction to obtain tetrahydrofuran solution of a midbody 2; and then mixing the midbody 1 and the midbody 2 with tetrahydrofuran, carrying out amidation to obtain a crude product of roflumilast, and refining the crude product of roflumilast to prepare the roflumilast material. Aiming to overcome the shortage of the prior art, the preparation process of the roflumilast material is optimized, so that the curative effect for treating diseases such as chronic obstructive pulmonary disease (COPD) is more remarkable; and besides, a systematic, complete and effective composition identifying and content measuring method is provided, so that the quality of the medicine can be effectively controlled, and the clinical effect is ensured.

The invention relates to an open-throat sword spray used for treating throat diseases and a preparation method thereof, and relates to a drug which has the effects of clearing heat and removing toxicity and relieve swelling and pains, and is used for treating diseases such as acute laryngopharyngitis, chronic laryngopharyngitis, amygdalitis, swollen sore throat, stomatitis, dental ulcer, dry mouth and bitter mouth, swollen gums, recurrent oral ulcer and the like, and particularly relates to an oral preparation prepared by using four traditional Chinese medicinal materials containing ardisia crenata sims, radix sophorae tonkinensis, cicada slough and menthol as raw materials. Compared with a conventional method, the method has optimized extraction process parameters, increased transfer rate of active ingredients and increased yield. Besides, the method has more stable and reliable quality, better effect curative effects and better security.

A composite medicine with high solubility, stability and activity and low hemolytic irritation contains cefteram ester and the pharmacologically acceptable dextrin chosen from beta-cyclodextrin and its derivatives. Its preparing process is also disclosed.

The invention relates to a drug interaction modeling and risk evaluation method, terminal equipment and a storage medium. The method comprises steps that S100, a drug combination list from an electronic medical record database is obtained, and a drug interaction risk evaluation model is constructed according to the drug combination status therein; S200, to-be-inquired drug names are inputted in the drug interaction risk evaluation model, if the drug interaction risk evaluation model already has the drug combination status information of the to-be-inquired drug group, the corresponding drug interaction risk evaluation information is outputted; S300, if not, the component information of drugs in the drug group is utilized to construct a drug similarity matrix, in combination with the drug similarity matrix and the drug interaction risk evaluation model, the corresponding drug interaction risk evaluation information is outputted. The method is advantaged in that the drug interaction riskevaluation information is outputted through the drug interaction risk evaluation model, and accurate and effective decision basis is provided for reasonable clinic drug combination.

The present invention relates to a sarcopeptidoglucoside powder injection and its preparation method. It is formed from polypeptide, hydroxanthine and excipient. Said invention adopts the modern biological extraction technique to prepare sarcopeptidoglucoside solution, and utilizes the modern low-temp. freeze-drying preparation technique to obtain the invented sterile freeze-dried powder injection. When it is used, it can be dissolved by injection water or infusion fluid, then can be injected. Said invention has good stability, long storage time and high safety, etc.

The invention discloses clopidogrel bisulfate crystal particles with the median particle diameter of at least 120 microns. The invention also discloses a method for preparing the crystal particles, a pharmaceutical composition containing the crystal particles and a preparation method of the pharmaceutical composition.

A process for preparing the injection of carnosine features that the chitosan and oligose are used for adsorbing the modified protein and fat to improve the purity of product, and the 6-aminopurine phosphate is used as the protector for increasing the sterilizing temp and time to 121 deg.C and 30 min, so having no bacterial pollution.

The invention relates to the technical field of transfusion monitoring, and discloses a physician, nursing and pharmacy integrated omnibearing reasonable safety transfusion early-warning monitoring method. The method comprises the following flow: receiving a transfusion prescription and doctor advice information from a doctor work station, extracting pharmacy information, examination information and vital sign information from the prescription and doctor advice information; selecting a transfusion pharmacy knowledge base from a reasonable safety transfusion knowledge base rule base, wherein the reasonable transfusion pharmacy knowledge base comprises pharmacy rule information, clinic rule information, a medicine and pharmacy literature database and public prescription evaluation rule information. The method provided by the invention achieves the automatic screening and evaluation of the infusion reaction risks through the biochemical indexes of a patient, achieves the safety checking of a tool, achieves the marking and prompt of dripping speed, light avoiding and transfusion stable time, helps a nurse carry out the medication safety monitoring and take measures, and guarantees themedication safety.

The invention relates to a character DNA sequence of dendrobium officinale tube seedling and the application. The invention discloses a character DNA sequence of dendrobium officinale tube seedling, which is the DNA sequence of SEQ ID NO: 1or the complementary sequence. The invention also discloses a usage for utilizing specificity probe of dendrobium officinale tube seedling in identifying dendrobium officinale tube seedling and an identifying method. The character DNA sequence of dendrobium officinale tube seedling which is used to identify dendrobium officinale tube seedling and dendrobium officinale has high accuracy and excellent specificity, the identification technique is easy to master.

The invention provides a membranous milkvetch root extract, as well as preparation and application methods thereof. The extract is extracted by taking traditional Chinese medicine membranous milkvetch root as a raw material, and the extract contains the following components in percentage by weight: 0.66%-0.73% of calycosin, 0.36%-0.42% of onocol and 34.6%-36.9% of total saponins from membranous milkvetch root. The preparation method of the extract disclosed by the invention takes the content of the calycosin, the content of the onocol, the content of the total saponins from the membranous milkvetch root, the water content, the residue on ignition and the content of heavy metals in the extract as indexes for optimization. According to the preparation method provided by the invention, the quality of the membranous milkvetch root extract can be better controlled, the safety in medication can be ensured, and membranous milkvetch root medicaments with controllable quality and clear material base can be deeply developed for complying with the requirements of traditional Chinese medicine modernization.